A parent is told the antibiotic their child needs is out of stock. A cancer patient is switched to a different treatment because the usual medicine cannot be sourced. A pharmacist spends half the day ringing wholesalers instead of advising patients. When people ask why are medicines unavailable, they are rarely asking about logistics alone. They are asking why a wealthy, highly regulated region still cannot reliably deliver essential treatment.
Medicine shortages are no longer an occasional disruption. Across Europe, they have become a recurrent public-health problem with consequences for patient safety, trust in institutions and equality of access. The immediate explanation is often simple – a product is out of stock. The real explanation is not. It sits at the intersection of industrial policy, market incentives, regulation, geopolitics and the basic fact that modern pharmaceutical supply chains are far more fragile than many health systems were built to assume.
Why are medicines unavailable in the first place?
The short answer is that medicines become unavailable when demand, production and distribution fall out of balance. That imbalance can be caused by one event, but more often it is caused by several smaller pressures hitting at once.
A manufacturer may face a problem at a single production site. An active ingredient may be delayed at the border. A low-priced generic may no longer be commercially attractive in one market. A sudden winter surge in infections may empty stocks that were planned for a milder season. By the time patients hear there is a shortage, the problem often began months earlier.
This is why shortages are difficult to fix quickly. Medicines are not ordinary consumer goods. Production is tightly regulated, quality standards are high for good reason, and replacing one supplier with another can take time. If only a handful of firms make a particular product, one factory issue can ripple across several countries.
The hidden fragility of pharmaceutical supply chains
Europe has sophisticated health systems, but many medicines rely on global manufacturing chains that stretch well beyond the continent. Active pharmaceutical ingredients and finished products may be made in different countries, moved through several intermediaries and packaged elsewhere before reaching a local pharmacy or hospital.
That model can lower costs, but it also creates concentration risk. If a small number of sites produce a widely used ingredient, any disruption – contamination, energy shortages, export restrictions, labour problems or transport delays – can have outsized effects. A medicine can disappear from shelves not because Europe lacks demand, but because its supply chain was optimised for efficiency rather than resilience.
This matters especially for older generics. These medicines are often essential, widely prescribed and relatively cheap. Yet low prices can discourage investment in backup production capacity. The public expects them to be continuously available, while the market often rewards manufacturers for cutting margins to the point where redundancy disappears.
Pricing policy can make shortages worse
One politically uncomfortable answer to why are medicines unavailable is that some shortages reflect how medicines are purchased and priced. Governments and insurers understandably seek to contain spending. Tender systems and reference pricing can lower costs for public budgets and patients. But if those systems drive prices too low, some suppliers exit the market or reduce supply commitments.
That does not mean lower prices are wrong. It means there is a trade-off. A health system can save money on procurement while becoming more exposed to disruption if only one or two companies remain willing to supply a medicine. When a single low-cost supplier falters, there may be no immediate alternative.
Smaller markets can be particularly vulnerable. If companies prioritise larger or more profitable countries during shortages, patients in less commercially attractive markets may face delays first. That raises a fairness question as well as an economic one. Access to essential medicines should not depend on whether a country has greater purchasing power or bargaining leverage.
Regulation protects patients, but it can slow recovery
Regulation is not the villain here. Strict oversight exists because medicines that are contaminated, ineffective or wrongly labelled can cause direct harm. But it is also true that regulatory systems designed for safety can move too slowly when shortages emerge.
A manufacturer cannot simply switch a site, change a source of ingredients or alter packaging overnight. Variations need approval. Quality inspections take time. National rules can differ. Information may not move quickly enough between companies, regulators, wholesalers and pharmacists.
At European level, authorities have become more alert to this problem, particularly after the pandemic exposed strategic dependencies in medical supply. Yet coordination still has limits. A medicine may be authorised at EU level but distributed through national systems with different reimbursement rules, stock practices and reporting standards. The result is a patchwork response to what is often a cross-border problem.
Demand shocks are more common than policy-makers admit
Not every shortage begins with supply failure. Sometimes demand rises far beyond expectations. A bad flu season, a spike in respiratory infections, war-related displacement, panic buying or new clinical guidance can all trigger sudden demand surges.
These shocks expose how tightly many systems are run. Hospitals and pharmacies do not hold unlimited reserves, and manufacturers do not keep vast idle stock waiting for emergencies. That may be rational from a business standpoint, but it leaves little room for public-health surprises.
The pandemic made this unmistakable, but the lesson was broader than Covid-19. Health systems had become used to just-in-time delivery for products that citizens experience as non-negotiable essentials. That mismatch between public expectation and supply-chain design is still with us.
Shortages are not only a market issue – they are a governance issue
Medicine availability is often discussed as a technical problem. It is also a governance test. If authorities do not collect timely shortage data, do not share clear guidance, or fail to coordinate across borders, the burden falls on patients and front-line professionals.
Pharmacists are left to improvise. Doctors must change prescriptions at short notice. Patients with chronic conditions may travel from one chemist to another or go without treatment for days. Those with money, information or mobility cope better than those without. In practice, shortages can deepen existing inequalities, especially for older people, disabled patients, carers and those in rural areas.
This is where transparency matters. Patients should not have to depend on rumours, social-media posts or repeated phone calls to understand whether a medicine is unavailable temporarily, nationally or only at one outlet. Better reporting systems would not solve shortages on their own, but they would reduce confusion and unsafe workarounds.
What can actually reduce medicine shortages?
There is no single fix, and politicians should be wary of promising one. Bringing more pharmaceutical production back into Europe may improve resilience for some medicines, but it will not erase every bottleneck and could increase costs. Strategic stockpiles sound attractive, but they require careful management and are more useful for some products than others. Faster regulatory flexibility can help, but not if it weakens safety standards.
The more credible approach is layered. Health authorities need better early-warning systems, clearer shortage reporting and stronger cross-border coordination. Procurement systems should consider security of supply, not price alone. For critical medicines, governments may need to support diversified manufacturing or maintain reserve capacity that the market would not sustain by itself.
There is also a case for distinguishing between ordinary commercial products and medicines that are systemically important. If an injectable antibiotic, insulin product or cancer therapy is essential to public health, treating it as just another low-margin commodity invites predictable failure.
What patients can do when medicines are unavailable
For individuals, the practical reality is less grand. If a prescribed medicine is unavailable, the safest first step is to speak to the pharmacist promptly. Sometimes the issue is local rather than national, and another formulation or supplier may be available. If not, the prescriber may need to authorise an alternative.
Patients should not stop, split or substitute medicines on their own, especially for epilepsy, heart disease, mental health conditions or hormone-related treatment. Even when an alternative exists, dosage, absorption or side effects may differ. Asking whether the shortage is expected to be brief or prolonged can also help people plan repeat prescriptions earlier next time.
For those managing long-term conditions, keeping a modest buffer within the limits of medical advice is sensible. Stockpiling is not. When individuals hoard scarce medicines, shortages often worsen for everyone else.
Why this issue will remain politically sensitive
Medicine shortages strike at a basic social contract. Citizens pay taxes, contribute to insurance systems and accept extensive pharmaceutical regulation in the expectation that essential treatment will be there when needed. When it is not, confidence in both markets and institutions begins to fray.
That is why the question why are medicines unavailable cannot be brushed aside as a routine supply problem. It touches industrial dependence, public procurement, European coordination and the rights of patients to timely care. It also reveals something larger about modern governance: systems built for efficiency can become brittle when resilience is treated as expendable.
The test for Europe is not whether every shortage can be eliminated. It cannot. The test is whether public authorities are willing to treat medicine availability as a matter of accountability rather than inconvenience. Patients should not have to become supply-chain detectives to receive ordinary care.
